You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
Sign In
{{'GLOBAL_MESSAGE_HEADLINE' | translate}}
{{'GLOBAL_MESSAGE_CHOOSE_LANG' | translate}}
en
日本語
中文
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'GLOBAL_MESSAGE_SET_COUNTRY' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}
{{'MP_LVL1NAV_PRODUCTS_SERVICES' | translate}}
{{d.Title}}
{{psData[masterIndex].Blurb}}
{{s.Title}}
{{l.Title}}
{{n.Title}}
{{n.Blurb}}
{{s.Title}}
{{l.Title}}
Welcome, {{userName}}
{{'MP_HEADER_LOG_IN' | translate}}
{{countryCode}}
{{'SEARCH_MODAL_TITLE' | translate}}
{{'MP_LVL1NAV_PRODUCTS_SERVICES' | translate}}
{{c.Title}}
{{s.Title}}
{{l.Title}}
{{n.Title}}
{{s.Title}}
{{l.Title}}
Spectra Optia
®
Cell Collection Services
Overview
Services
Materials
Cell Therapy Technologies
Gain Insight and Control Through Your Cell Collection Data
The best possible starting material is critical to providing the best outcome.
Optimize Your Starting Material
Use Data to Drive Improvement of Your Cell Collections
Your manufacturing process is highly dependent on the quality of your starting material. Whether you are just starting your CAR T-cell therapy clinical trial or scaling up from phase 1 to phase 2, the starting material collected from the patient matters. No two patients are the same and collections can vary. Controlling what you can becomes all the more important.
Let our expertise paired with your procedural data provide a roadmap for achieving your goals.
Enhanced strategy
Data-driven decisions
Visibility into the process
Optimized starting product
Achievement of therapy objectives
Variability in CAR T-cell expansion may cause the contamination of the starting peripheral blood mononuclear cell (PBMC) concentrates with monocytes (non-target cells).
1
Our Services
Spectra Optia Cell Collection Data Analytics
Single or multiple procedure data analysis
Comprehensive analysis from pre-procedure data through final therapy results
Optimization recommendations
Collection site comparison and benchmarking
On-site and off-site systems support
Spectra Optia Prediction Algorithm
Collection data review
Customized whole blood process calculation
Statistical summary analysis
Contact us for a consultation with a data analysis specialist.
1
Stroncek DF, Ren J, Lee DW, et al. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T Cells.
Cytotherapy
. 2016;18(7):898-901.
Materials
White Paper: Cell Collection Basics – Introduction and Fundamentals for HSCT and C> Industries
Download
Case Study: Data Analysis of HSC Collections Helps Improve Performance and Reduce Collection Days
Download
Customer Success Story: Hospital Increases the Mean Hematopoietic Stem Cell Yield Yield and CD34+ Collection Efficiency By 32%
Download
Customer Success Story: Improved cell collections of target yields from 47% to 92%
Download
Veda Solutions: Spectra Optia Cell Collection Analytics Brochure
Download
On-Demand Webinar: Challenges of Cell Collections for Cell Therapy Manufacturing: What Do We Want in the Bag?
Panel includes Krishnendu Roy, PhD; Sandeep Soni, MD; and Melinda Caltabano
Register Now
Page Content
{{'SEARCH_MODAL_TITLE' | translate }}
{{s.Query|stripSpecialChars}}
{{'SEARCH_MODAL_OR' | translate }}
{{'SEARCH_MODAL_BROWSE' | translate }}
{{'SEARCH_MODAL_ENLABEL' | translate }}
{{'SEARCH_MODAL_PRODUCT' | translate }}
{{productCode.RefinementName}}
{{'SEARCH_MODAL_CATEGORY' | translate }}
{{categoryCode.RefinementName}}
{{'SEARCH_SMODAL_SEGMENT' | translate }}
{{segmentCode.RefinementName}}
{{'SEARCH_MODAL_SHOW_BROWSE_RESULTS' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }}
{{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}